Entities / Company
Servier.
company in Madrid, Spain
- Reports this week
- 0
- Active events
- 0
- Connections
- 13
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Servier and Ideaya Biosciences entered an exclusive license agreement on September 2, 2025.Some support1 report1 development inside
-
Servier has been named as a global partner in the OptimUM-11 clinical trial.Some support1 report
-
Former president of the European Society of Cardiology (ESC) faced misconduct allegations regarding their tenure, which was affiliated with Imperial College London and involved drug trials.Some support3 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Servier this week
News at the entities that move Servier most-
Insilico Medicine OperationalInsilico Medicine developed PLSI for the Grok Bot platform in collaboration with David Sinclair, a researcher from Harvard Medical School.Moves Servier
-
Ligand Pharmaceuticals StructuralLigand Pharmaceuticals filed a transaction with the SEC, while Royal Bank of Canada lifted its target price, and the stock is listed on Nasdaq.Moves Servier
Connections
The 4 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Insilico Medicine Operational
The two companies are engaged in announced drug discovery collaborations.
-
Kim Fox Transactional
Kim Fox was involved in drug trials and profited from contracts with Servier.
-
European Society of Cardiology Structural
Servier's drug trial data influences ESC guideline recommendations, which in turn regulate drug use.
-
Ligand Pharmaceuticals Structural
The relationship is functional, based on assets acquired via a specific XOMA Royalty deal.